Naomi Kamau

As a Clinical Trial Manager within the Nuffield Department of Primary Care Health Sciences, University of Oxford, I am currently overseeing a UTI trial that seeks to determine the optimal duration of antibiotic treatment for urinary tract infections (UTI) in women. I joined the Clinical Trials Unit in October 2022 as the Trial Manager for the DURATION UTI study, and have since been instrumental in leading the project to its current stage.

Prior to my current role, I served as a Clinical Trial Coordinator at the Kenya Medical Research Institute's Centre for Geographic Medicine Research Coast (KEMRI-CGMRC) in Kilifi,Kenya. During this time, I managed several multicentre vaccine trials accross Kenya and East Africa at large, which were sponsored by the University of Oxford and MSF Epicentre in France. My primary responsibilities included overseeing the timely and successful delivery of trials within the designated budget and scope, engaging with stakeholders, and ensuring the delivery of quality study results.

Some of the trials that i managed included a Phase 1b/II ChAdOx1 nCoV-19 Vaccine trial that evaluated the safety, immunogenicity, and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in Kenyan adults. Additionally, I managed two Phase IV Yellow Fever vaccine studies, namely YEFE and NIFTY, that evaluated the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda. Finally, I managed a Phase I Rift Valley Fever Virus (RVFV) vaccine trial (ChAdOx1 RVF) that evaluated the safety and efficacy of a new Rift Valley Fever vaccine.

Through my various roles and responsibilities, I have developed a strong skill set that includes effective stakeholder engagement, adherence to timelines and budgets, and a commitment to delivering quality study results.